Study Shows Effient Not Superior To Plavix, But Bleeding Risk Similar
This article was originally published in The Pink Sheet Daily
Executive Summary
A study published in the New England Journal of Medicine showed Effient was not superior to Plavix in treating patients who had not undergone revascularization.
You may also be interested in...
AstraZeneca Faces Uphill Battle In Talking U.S. Docs Into Using Brilinta
U.S. physicians say skepticism over the North American results in the pivotal PLATO study is one of many factors that’s been slowing adoption. Competition with low-cost generics is another.
AstraZeneca Aims To Shake Plavix Off The Throne With Launch Of Brilinta In China
AstraZeneca launches Brilinta in China, aiming to grow its share of a $1.5 billion antithrombotic market at the expense of Sanofi’s Plavix.
AstraZeneca Aims To Shake Plavix Off The Throne With Launch Of Brilinta In China
AstraZeneca launches Brilinta in China, aiming to grow its share of a $1.5 billion antithrombotic market at the expense of Sanofi’s Plavix.